Stockscreener 앱 받기
0.9096
3.36%
0.0296
시간 외 거래:
.94
0.0304
+3.34%
Inflarx N V 주식(IFRX)의 최신 뉴스
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
InflaRx FY 2025 earnings preview - MSN
Aug Opening: Is InflaRx NV forming bullish engulfing patterns2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Aug Levels: Can InflaRx NV outperform under higher oil prices2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
InflaRx (IFRX) director Mark Kubler reports 960,015 shares and multiple options - Stock Titan
InflaRx (IFRX) director lists options and 10,000 Ordinary Shares - Stock Titan
InflaRx (IFRX) director details vested and future stock options - Stock Titan
InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants - Stock Titan
InflaRx (IFRX) officer discloses vested and performance stock options - Stock Titan
InflaRx (IFRX) director discloses sizeable share and option stakes - Stock Titan
InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants - Stock Titan
InflaRx (IFRX) CFO details extensive stock option and share holdings - Stock Titan
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
InflaRx N.V. to Present Phase 3 Study Data on Vilobelimab for Pyoderma Gangrenosum at AAD 2026 Annual Meeting - Quiver Quantitative
Vilobelimab Phase 3 data earns late-breaker slot at AAD 2026 meeting - Stock Titan
InflaRx NV expected to post a loss of 15 cents a shareEarnings Preview - TradingView
InflaRx (IFRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
InflaRx receives Nasdaq notification - MSN
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Sahm
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price - National Today
InflaRx (IFRX) hit with Nasdaq minimum $1 bid-price warning and cure window - Stock Titan
InflaRx receives Nasdaq notice over minimum bid price rule - Investing.com
InflaRx to Report Full Year 2025 Results on March 19, 2026 - Bitget
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
IFRX: Izicopan advances as a lead asset with strong HS data, new indications, and global expansion plans - TradingView
Breakout Move: Can InflaRx N.V. stock maintain growth trajectoryWeekly Trend Report & Growth Focused Stock Reports - Naître et grandir
Market Leaders: Is InflaRx NV a top pick in the sectorGap Down & Weekly Stock Performance Updates - baoquankhu1.vn
What RSI levels show for InflaRx N.V. (IF0) stock2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - Naître et grandir
Shorts Report: Can APCXW maintain sales growthTrade Volume Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Analysts Set InflaRx N.V. (NASDAQ:IFRX) Target Price at $7.50 - Defense World
IFRX Earnings History & Surprises | EPS & Revenue Results | INFLARX NV (NASDAQ:IFRX) - ChartMill
Aug Macro: Whats the analyst consensus on InflaRx NV2025 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - Bitget
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference - MarketBeat
InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
IFRX Should I Buy - Intellectia AI
IFRX PE Ratio & Valuation, Is IFRX Overvalued - Intellectia AI
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit - MarketBeat
IFRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will InflaRx N.V. stock continue dividend increasesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - mfd.ru
Is InflaRx N.V. (IF0) stock among top earnings playsPortfolio Update Summary & Growth Oriented Trading Recommendations - mfd.ru
Treasury Yields: Is InflaRx NV forming bullish engulfing patternsEarnings Risk Summary & Smart Investment Allocation Tips - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus PT from Analysts - Defense World
Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
InflaRx launches public offering of shares and warrants - MSN
How strong is InflaRx N.V. stock revenue growthWeekly Profit Report & Growth Oriented Trading Recommendations - mfd.ru
1.20%
0.06%
자본화:
|
볼륨(24시간):